Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasms 2Neoplasm Metastasis 2Glioma 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Thoracic Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma, Kaposi 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Newly Diagnosed Glioblastoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Multiple Myeloma 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Melanoma 1Lymphopenia 1Lymphoma, Non-Hodgkin 1

Interventions

Etoposide 154Carboplatin 142Cisplatin 104Topotecan 74durvalumab 48atezolizumab 46Irinotecan 44pembrolizumab 39Paclitaxel 34Nivolumab 33Radiotherapy 29anlotinib 23PM 01183 22Gemcitabine 21Drug Therapy 20apatinib 19Ipilimumab 18Docetaxel 17Temozolomide 16Platinum 16Radiosurgery 15Pemetrexed 14toripalimab 13tislelizumab 13olaparib 13Bevacizumab 13amrubicin 11Magnetic Resonance Spectroscopy 11Cyclophosphamide 11rovalpituzumab tesirine 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Small Cell Lung Carcinoma × efineptakin alfa × Clear all
NCT04332653 2026-03-09

NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

NeoImmuneTech

Phase 1/2 Completed
215 enrolled 30 charts
BreastGastrointestinalGynecologicThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Thoracic Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡